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Background: The percentage of older HIV-positive patients is growing, with an increase in 
age-related comorbidities and concomitant medication.
Objectives: To quantify polypharmacy and profile types of non-antiretroviral drugs collected 
at community pharmacies in 2014 by HIV-positive individuals on antiretroviral therapy and to 
compare these findings with those of the general population.
Methods: HIV-positive patients (n=199) were compared with a group of patients from the gen-
eral population (n=8,172), aged between 50 and 64 years. The factors compared were prevalence 
of polypharmacy ($5 comedications with cumulative defined daily dose [DDD] per drug over 
180), percentage of patients who collected each therapeutic class of drug, and median duration 
for each drug class (based on DDD). Results were stratified by sex.
Results: Polypharmacy was more common in HIV-positive males than in the male general 
population (8.9% vs 4.4%, P=0.010). Polypharmacy was also higher in HIV-positive females 
than in the female general population (11.3% vs 3.4%, P=0.002). Percentage of HIV-positive 
patients receiving analgesics, anti-infectives, gastrointestinal drugs, central nervous system 
(CNS) agents, and respiratory drugs was higher than in the general population, with significant 
differences between male populations. No differences were observed in proportion of patients 
receiving cardiovascular drugs. The estimated number of treatment days (median DDDs) were 
higher in HIV-positive males than in males from the general population for anti-infectives (32.2 vs 
20.0, P,0.001) and CNS agents (238.7 vs 120.0, P=0.002). A higher percentage of HIV-positive 
males than males from the general population received sulfonamides (17.1% vs 1.5%, P,0.001), 
macrolides (37.1% vs 24.9%, P=0.020), and quinolones (34.3% vs 21.2%, P=0.009).
Conclusion: Polypharmacy is more common in HIV-positive older males and females than in 
similarly aged members of the general population. HIV-positive patients received more CNS 
drugs and anti-infectives, specifically sulfonamides, macrolides, and quinolones, but there were 
no differences in the percentage of patients receiving cardiovascular drugs. It is essential to 
investigate nonantiretroviral therapy medication use in the HIV-positive population to ensure 
these patients receive appropriate management.
Keywords: polypharmacy, HIV infection, aging
Introduction
The mean age of patients with HIV infection is increasing. This is mainly due to 
increased life expectancy as a result of effective antiretroviral therapy (ART)1,2 
and, in Spain, there is an increase in the percentage of patients diagnosed at an 
older age.3 The introduction of highly active ART has changed the face of HIV 
infection by considerably reducing morbidity and mortality, improving quality of 
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life, and increasing life expectancy.4,5 In a study from the 
Netherlands, Smit et al predicted that by 2030, 73% of their 
HIV-positive patients would be aged $50 years.6 In the 
context of HIV infection, the term “older” refers to patients 
aged $50 years.7,8
The combined impact of HIV infection and the risk 
of noncommunicable diseases can add to the disease 
burden of aging HIV-positive individuals. Comorbidities 
are more numerous and occur at a younger age in this 
aging population than in the general population; this does 
not occur in the younger HIV population.9–11 The medi-
cal management of older HIV-positive individuals brings 
with it the management of polypharmacy. The problems 
associated with polypharmacy include worse medication 
adherence, increased risk of adverse drug events, use of 
inappropriate drugs, hospitalization, geriatric syndromes, 
and mortality.12–15
Relatively few studies have analyzed the extent of 
polypharmacy in older HIV-positive individuals or the 
classes of drugs prescribed or their effects on drug–drug 
interactions.16–20 Furthermore, such studies do not specify 
treatment doses or duration of long-term treatments and 
use drug consumption data based on clinical notes and/
or patient self-reports, which are potential sources of bias 
and errors.21,22
A previous study by our team in 2011 analyzed non-ART 
medication in the HIV-positive population aged $50 years, 
and compared this with the findings in the general popu-
lation.23 Medications were analyzed at the second level 
of the World Health Organization (WHO) Anatomical 
Therapeutic Chemical (ATC) classification, and only male 
patients were compared. The present study included a larger 
number of HIV-positive patients and a sample of the general 
population with the same age and sex distribution as the 
HIV-positive population. Normally, the general population 
has a more even distribution of age and sex, something that 
does not occur in the HIV-positive population. This study 
also included an analysis between females; this was not 
performed in our previous study from 2011. Furthermore, 
a more global analysis of medication use was performed, 
analyzing all drugs used by organ or system, allowing a more 
comprehensive evaluation.
The purpose of the present study was to determine the 
prevalence of polypharmacy in older HIV-positive males 
and females, by analyzing the number and types of drugs 
dispensed at pharmacies over a year, and to compare our 
findings with those for a sample of the general population 
with the same age and sex distribution.
Methods
We performed a descriptive retrospective study of HIV-
positive individuals aged 50–64 years and receiving out-
patient ART at a university hospital pharmacy in Aragón, 
Spain, between January and December 2014. We chose 
a cutoff age of 64 years because there are relatively few 
HIV-positive patients older than 64 in the population served 
by our hospital. In Spain, hospital pharmacies dispense all 
ART prescriptions to HIV-positive individuals from the 
surrounding geographic area: in this case, a population of 
299,934. ART is only dispensed in hospital pharmacies, not 
in community pharmacies. Patients receiving postexposure 
prophylaxis were excluded from the study, as these patients 
do not have a diagnosis of HIV.
The study was approved by the Aragón Clinical Research 
Ethics Committee. Patient consent was not necessary because 
it was an observational retrospective study, with no interven-
tion. It forms part of a larger project entitled “Antiretroviral 
therapy in HIV-naïve patients and use of concomitant medi-
cation in older HIV-infected patients”, which is regulated 
by the Aragonese Government (Royal Decree 223/2004 and 
Decree 26/2003, modified by Decree 292/2005).
The reference population was a random sample of 
8,172 patients, from a general population of 54,798 aged 
50–64 years and from the same geographic area as the 
HIV-positive population. The age and sex distribution of 
the general population sample and the HIV population were 
similar. We calculated the size of the general population 
sample needed to estimate the proportion of people being 
treated with each class of drug.
The study variables included patient date of birth, sex, 
and the following HIV infection-related variables: date of 
HIV diagnosis, date of ART initiation, HIV plasma viral 
load (copies/mL), and CD4 cell count at the last study visit, 
and antiretroviral drugs received at completion of the study 
period. This information was compiled from medical records 
and the pharmacy-dispensing program.
Drugs dispensed from community pharmacies defined 
as those with a medical prescription covered by the public 
health system and registered in the district-level Aragonese 
Consumption of Pharmaceuticals Information System, from 
January 1, 2014 to December 31, 2014, were also collected. 
The analysis excluded antiretroviral medications, medica-
tions that do not require a physician’s prescription, medica-
tions that do not have a defined daily dose (DDD) such as 
eye drops and creams, drugs prescribed in the private health 
care setting, and medicinal plants. Sum of DDD of each drug 
per patient was calculated. In addition to ethical approval, we 
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received permission to access the Aragonese Consumption 
of Pharmaceuticals Information System Database using an 
anonymized view.
The proportion of HIV-positive patients and of the general 
population patients that collected drugs from different thera-
peutic classes and from each therapeutic subgroup of drugs 
was compared. A detailed analysis was performed using 
the therapeutic subgroups, which showed large differences 
between the HIV-positive patients and general population.
The median duration of treatment for each therapeutic class 
of drugs and for each therapeutic subgroup in the HIV popula-
tion and the general population (based on the median DDD of 
the sum of all drugs within each class) was also compared.
To determine the number of non-ART drugs per patient 
per year, we used the following conditions: 1) each prescrip-
tion collected was considered to correspond to one medica-
tion taken and 2) long-term treatments were divided into 
treatments lasting .90 days (.90 DDD/drug/patient/year) 
or .180 days (.180 DDD/drug/patient/year).24,25 Polyp-
harmacy was defined as the use of five or more concomitant 
medications in three possible contexts: drugs with DDD .1, 
DDD .90, or DDD .180. Five concomitant medications is 
generally accepted as the threshold associated with negative 
health outcomes.12,26,27
Each drug was assigned to a therapeutic subgroup accord-
ing to the second level of the 2015 version of the WHO 
ATC classification system.28 Drugs were also classified into 
six broad therapeutic classes:16 analgesics, anti-infectives, 
gastrointestinal (GI) drugs, central nervous system (CNS) 
agents, cardiovascular drugs, and respiratory drugs. Sub-
sequently, a detailed analysis was performed of the drugs 
within the subgroups, which showed a large difference 
between populations.
We calculated the DDD for each drug taken by each 
patient during the study year. According to WHO, DDD is 
“the assumed average maintenance dose per day for a drug 
used for its main indication in adults”, and does not neces-
sarily reflect the recommended or prescribed daily dose. 
For example, the DDD of amlodipine is 5 mg. If a person 
collects 300 5 mg tablets of amlodipine in a year, the DDD/
drug/year is 300; if this person collects 300 10 mg tablets 
of amlodipine, the DDD/drug/year is 600. The DDD is a 
technical unit of measurement, used in combination with the 
ATC system that allows the quantification of annual drug 
consumption and overall comparison of drug use between 
different populations. The primary purpose of the ATC/
DDD system, as reported by WHO, is to “serve as a tool 
for drug utilization research in order to improve quality of 
drug use”. The use of DDD was considered to correspond to 
the duration of treatment, and the calculation of the DDDs 
in the therapeutic subgroups was performed as follows: all 
the DDDs for one drug for one patient were added, then the 
DDDs for all the drugs that make up a therapeutic subgroup 
in that patient were added, and then the median DDD of this 
drug group was calculated from all the patients receiving a 
drug from that group.
Data analysis was stratified by sex, as drug use has been 
found to differ between males and females.20,26
statistical analyses
In order to estimate the proportion of individuals in the 
general population treated with different medications, a 
sample was taken of the general population aged 50–64 years 
(n=54,798). This sample had the same age and sex distribu-
tion as the HIV-positive population. To calculate the sample 
size needed, we used a confidence level of 95%, precision of 
1%, and an expected proportion of 50%.
Qualitative data are expressed as frequencies and per-
centages, and quantitative data as medians and interquartile 
range (IQR) (25th to 75th quartile). Qualitative variables 
frequencies were compared using the chi-square test, and the 
means of nonnormally distributed data were compared using 
the Mann–Whitney U statistic. Analyses were performed 
using SPSS Version 15.0 (SPSS Inc., Chicago, IL, USA), 
University of Zaragoza license.
Results
There were 225 HIV-positive individuals $50 years who 
received ART from the hospital pharmacy services, rep-
resenting 30.7% of all HIV-positive patients who used this 
service between January 1 and December 31, 2014. Three 
individuals received postexposure prophylaxis, and there 
were 23 individuals .64 years. Ultimately, therefore, 
199 HIV-positive patients were included in the study.
hIV-positive population description
The study included 199 HIV-positive patients (73.4% 
males) aged 50–64 years. Of these, 66.8% were aged 
between 50 and 54 years. The median time since diagnosis 
was 18 years (IQR, 10.1–24.0), and the median duration 
of ART was 14.7 years (IQR, 8.2–18.0). At the last study 
visit, HIV-1 plasma viral load was .50 copies/mL in 8.1% 
of patients, and the median CD4 count was 659 cells/mcL 
(IQR, 444.2–999.7) (Table 1).
The families of antiretroviral drugs received by the 
patients at study completion were as follows: 1) 52.7% of 
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patients were treated with protease inhibitors, specifically, 
darunavir, lopinavir, and atazanavir, at 36.2%, 9.5%, and 
7.0%, respectively; 2) 47.7% of patients received a nonnucle-
otide reverse transcriptase inhibitor, specifically etravirine, 
nevirapine, efavirenz, and rilpivirine, at 18.1%, 12.1%, 
11.6%, and 6.0%, respectively; 3) 73.4% were treated with a 
nucleoside reverse transcriptase inhibitor, specifically, teno-
fovir disoproxil fumarate/emtricitabine, abacavir/lamivudine, 
lamivudine, and tenofovir disoproxil fumarate, at 38.7%, 
32.7%, 1.0%, and 1.0%, respectively; 4) 19.6% were treated 
with an integrase inhibitor, all with raltegravir; and 5) 1.5% 
received a CCR5 receptor antagonist, all with maraviroc.
Comparison of number of concomitant 
medications (not ArT)
The median number of concomitant medications received 
was higher in HIV-positive males than in males from the gen-
eral population (4 IQR [1–8] vs 2 IQR [0–5]; P,0.001).
The proportion of patients collecting at least one con-
comitant medication during the study year was higher in 
HIV-positive males than in males from the general population 
(80.1% vs 70.7% for any drug, P=0.013; 58.9% vs 48.8% for 
drugs with a DDD .90, P=0.016; and 48.6% vs 40.3% for 
drugs with DDD .180, P=0.043). Long-term polypharmacy 
($5 non-ART drugs) was more common in the HIV-positive 
males than in males from the general population for drugs 
with a DDD .90 (13.0% vs 8.8% of males, P=0.079) and a 
DDD .180 (8.9% vs 4.4%, P=0.010) (Figure 1A).
Of the 53 HIV-positive females and the 2,176 females 
from the general population, 84.9% and 80.1%, respectively 
(P=0.382) collected at least one concomitant medication dur-
ing the study year, and 47.2% and 40.4% (P=0.321) collected 
five or more. However, when long-term treatments were 
considered, a higher proportion of HIV-positive females than 
females from the general population were polymedicated ($5 
non-ART drugs), collecting drugs with a DDD .90 (18.9% 
vs 9.8%, P=0.030) and drugs with a DDD .180 (11.3% vs 
3.4%, P=0.002) (Figure 1B).
Therapeutic classes
A statistically significant higher proportion of HIV-positive 
male patients than male patients from the general population 
received analgesics, anti-infectives, GI drugs, CNS agents, 
and respiratory drugs. There were no differences in the 
percentage of patients who received cardiovascular drugs. 
Similarly, there were no significant differences between 
HIV-positive females and female controls regarding the 
therapeutic classes of drug used (Figure 2).
On comparing therapeutic subgroups, HIV-positive 
males were significantly more likely than males from the 
general population to be taking the following drugs: drugs 
for acid-related disorders (A02) 32.2% vs 24.1%, P=0.024; 
β-blocking agents (C07) 11.6% vs 6.8%, P=0.022; antibac-
terials for systemic use (J01) 47.9% vs 24.0%, P,0.001; 
analgesics (N02) 41.1% vs 23.7%, P,0.001; antiepileptics 
(N03) 12.3% vs 5.1%, P,0.001; psycholeptics (N05) 31.5% 
vs 16.0%, P,0.001; psychoanaleptics (N06) 13.0% vs 
7.0%, P,0.001; drugs for obstructive airway disease (R03) 
13.0% vs 6.2%, P=0.001; and antihistamines for systemic 
use (R06) 15.8% vs 9.1%, P=0.006.
One of the main differences in the therapeutic sub-
groups used between HIV-positive patients and the general 
population was the use of anti-infectives; therefore, a more 
detailed analysis of this was performed. A higher percentage 
of HIV-positive males than males from the general popu-
lation received antibiotics from the groups sulfonamides 
and trimethoprim (17.1% vs 1.5%, P,0.001); quinolones 
(34.3% vs 21.2%, P=0.009); and macrolides, lincosamides, 
and streptogramins (37.1% vs 24.9%, P=0.020). This 
increased consumption was mainly due to a higher per-
centage of HIV-positive males than males from the general 
population using cotrimoxazole (17.1% vs 1.5%, P,0.001), 
Table 1 Demographic and clinical variables of HIV-positive 
patients aged 50–64 years
Variable % (n) Median  
(P25–P75)
sex
Male 73.4 (146)
Female 26.6 (53)
Age, years 52 (51–56)
50–54 66.8 (133)
55–59 23.6 (47)
60–64 9.5 (19)
Time since hIV diagnosis, years (n=198) 18.0 (10.1–24.0)
#10 27.3 (54)
11–20 34.8 (69)
.20 37.9 (75)
Time since ArT initiation, years (n=190) 14.7 (8.2–18.0)
#10 33.7 (64)
11–20 51.6 (98)
.20 14.4 (28)
CD4 count, cells/mcl (n=198)
,200 3.5 (7)
200–350 14.1 (28)
351–500 15.6 (31)
.500 66.7 (132)
Vl, copies/ml (n=198)
,50 91.9 (182)
50–200 3.0 (6)
.200 5.1 (10)
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; 
Vl, viral load.
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azithromycin (34.3% vs 20.4%, P=0.005), levofloxacin 
(15.7% vs 5.2%, P,0.001), and moxifloxacin (11.4% vs 
5.1%, P=0.020).
Based on median DDDs, treatment duration was signifi-
cantly longer in HIV-positive males than in males from the 
general population for anti-infectives (32.2 vs 20.0 DDDs, 
P,0.001) and CNS agents (238.7 vs 120.0 DDDs, P=0.002). 
In HIV-positive females, treatment duration was significantly 
longer than in females from the general population for CNS 
agents (471.0 vs 140.0 DDDs, P=0.003), respiratory drugs 
(83.1 vs 45.0 DDDs, P=0.045), and GI drugs (364.0 vs 121.3 
DDDs, P=0.022) (Figure 3).
Figure 1 Concomitant medication use in hIV-positive patients and general population, aged 50–64 years.
Notes: (A) Males, (B) females. Use of 0, 1–4, and $5 prescribed concomitant medications (excluding antiretrovirals) was calculated according to 1) drugs with a DDD .1; 
2) drugs with a DDD .90 (treatments lasting .90 days); and 3) drugs with a DDD .180 (treatments lasting .180 days).
Abbreviations: DDD, defined daily dose; HIV, human immunodeficiency virus.
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Figure 2 Use of concomitant medication by therapeutic class and sex, in HIV-positive patients and general population, aged 50–64 years.
Abbreviations: CNS, central nervous system; HIV, human immunodeficiency virus.
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Treatment duration (median DDDs) was also significantly 
longer in the HIV-positive males than in males from the 
general population for antithrombotic agents (B01) (330.0 
vs 270.0, P=0.014), lipid-modifying agents (C10) (308.0 vs 
205.3, P=0.031), antibacterials for systemic use (J01) (27.7 
vs 20.0, P=0.001), and antipsycholeptics (N05) (177.5 vs 
60.0, P=0.001).
Discussion
We found a significantly higher prevalence of polypharmacy 
in the HIV group than in the general population, for both 
males and females. A higher proportion of HIV-positive 
patients received analgesics, anti-infectives, GI drugs, CNS 
agents, and respiratory drugs than in the general population. 
Cardiovascular drugs were used to a similar extent in both 
populations. The higher use of antibiotics in HIV-positive 
patients was due to sulfamethoxazole and trimethoprim, 
azithromycin, levofloxacin, and moxifloxacin use.
Previous studies have shown differences in the use of con-
comitant medications and therapeutic drug classes between 
older and younger HIV-positive patients.16,17,19 Our study 
published in 201523 also compared concomitant medication 
usage between HIV-positive individuals and the general 
population, but the present study adds several aspects to 
this. This study has a larger number of HIV-positive patients, 
increased from 130 in 2011 to 199 in 2014. Therefore, we 
were able to expand the comparative analysis of concomitant 
medication use in males in 2011, to perform it in females – a 
minority population in all HIV studies – in 2014. In addition, 
the population for comparison is a sample of the general 
population that is more similar in age and sex to the HIV 
population than in the previous study. Furthermore, drugs 
were grouped by organ or system, so that a more global 
analysis of their use could be performed.
The proportion of HIV-positive patients who collected 
five or more non-ART medications in our study is slightly 
lower than previously reported rates (43.8% and 47.2% for 
males and females, respectively, in our study compared with 
54.0% and 57.6% for both sexes in other studies).17,23 This 
difference could be due to the fact that, unlike other studies, 
we did not include alternative treatments. When long-term 
treatments (those with .90 or .180 DDDs) were taken 
into account, differences in polypharmacy prevalence were 
even greater at 13.0% and 8.9% for HIV-positive males 
and 18.9% and 11.3% for HIV-positive females. This may 
be due to differences in the methods used to calculate drug 
consumption and differences in the types of study performed, 
that is, previous cross-sectional studies versus our long-term 
study. While other studies used clinical notes and/or patient 
self-reporting, our study analyzed what patients actually 
collected from pharmacies. There is, of course, a risk that 
patients might not actually take their medications, but we 
believe that this method provides a more accurate picture of 
actual drug consumption.29,30
Use of analgesics, anti-infectives, GI drugs, CNS agents, 
and respiratory drugs was greater in the HIV-positive popu-
lation than in the general population. The differences were 
statistically significant for males but not for females; this 
Figure 3 Median days of treatment duration per patient (based on DDD), by therapeutic class and sex, over a 1-year period, in HIV-positive patients and general population, 
aged 50–64 years.
Note: Treatment duration was calculated using the median of sum of the DDDs for each medication within each therapeutic class.
Abbreviations: CNS, central nervous system; DDD, defined daily dose; HIV, human immunodeficiency virus.
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was probably because females were underrepresented in this 
HIV population. The findings of this study were consistent 
with previous findings by our group, which showed no dif-
ferences between the percentage of HIV-positive males and 
males from the general population receiving cardiovascular 
drugs such as renin–angiotensin inhibitors or lipid-lowering 
drugs.23 In the present study, there were no differences in car-
diovascular drug use between the two populations compared, 
independently of sex. The percentage of HIV-positive indi-
viduals receiving cardiovascular drugs in our study (39% of 
males and 34% of females) was lower than previous findings 
(53% and 65%, respectively).16,19 The results on cardiovascu-
lar drugs use were unexpected because cardiovascular disease 
is more prevalent in HIV-positive patients than in similarly 
aged members of the general population.9,11 Possible expla-
nations include underdiagnosis of cardiovascular disease 
in these patients, or lower rates of primary and secondary 
cardiovascular prophylaxis. It has been reported that only 
one of every five patients with HIV who are candidates for 
receiving aspirin as primary cardiovascular prophylaxis 
receive this treatment.31 Furthermore, a lower proportion of 
HIV-positive patients receive this prophylaxis compared with 
the HIV-negative population.32 In addition, it has been shown 
that a lower percentage of HIV-positive patients compared 
with HIV-negative patients receive lipid-lowering therapy, 
irrespective of the presence of cardiovascular disease.33 
However, in the absence of better data, we cannot offer a 
definitive explanation for this.
In accordance with earlier findings by our group,23 regard-
ing the percentage of patients who received certain drugs, 
the most notable differences were found for anti-infectives 
and CNS drugs. The higher rate of prescription of CNS 
drugs in HIV-positive patients can probably be explained by 
a higher prevalence of psychiatric disease, substance abuse, 
and drug dependence among HIV-positive individuals.34,35 
Despite good immunological control of HIV infection, 
antibiotics were prescribed to a considerably higher propor-
tion of the HIV population (47.9% of males and 47.2% of 
females) than the general population (24.8% of males and 
35.8% of females). A higher percentage of HIV-positive 
males were treated with trimethoprim/sulfamethoxazole, 
azithromycin, levofloxacin, and moxifloxacin. In the HIV 
population, cotrimoxazole is most commonly used as pri-
mary prophylaxis against Pneumocystis jirovecii in severely 
immunocompromised patients, as secondary prophylaxis 
in patients with previous P. jirovecii pneumonia, and as 
primary prophylaxis against Toxoplasma gondii.36 There is 
no obvious explanation for the higher use of azithromycin, 
levofloxacin, and moxifloxacin in HIV-positive patients; it 
could be due to more empirical and/or earlier use than in the 
general population, owing to the immunosuppressive nature 
of the infection, despite good CD4 levels. These antibiot-
ics are first line for respiratory infections, which are very 
common in the primary care setting. To this, we can add 
the probable use of antibiotics dispensed from pharmacies 
without a physician’s prescription, which, consequently, 
could not be included in this analysis.37
Compared with the general population, HIV-positive 
patients had longer durations of drug use, as defined by 
median DDDs (due to either the number of treatment days or 
higher doses). The differences were statistically significant 
for CNS agents (males and females), anti-infectives (males), 
and respiratory drugs (females) and GI drugs (females). 
Longer treatment with anti-infectives and CNS agents is 
consistent with previous findings by our group.23 The median 
DDD of CNS agents received per year by males with HIV 
was double than in males from the general population (238 
vs 120, P=0.002). This indicates that these drugs are used 
at a higher dose and for a longer time than in the general 
population. Regarding anti-infectives, the median DDD 
consumed by HIV-positive males was also higher than that 
for the general population (32.2 vs 20.0, P,0.001). As these 
treatments were for acute illnesses, this indicates either that 
there were a greater number of acute illnesses in the study 
year, or that the doses used were higher.
One strength of this study is that we measured drug con-
sumption, unlike previous studies that have provided figures 
based on clinical notes and patient self-reporting.16,18–20 Some 
studies distinguish between “polyprescription” (what the 
physician prescribes) and “polytherapy” (what the patient 
actually takes).38 As mentioned, we believe that pharmacy-
dispensed prescriptions provide a more accurate picture of 
actual drug use than physician prescriptions, because there 
can be differences between what is recorded in the clinical 
records (which can be split between the hospital and primary 
care), what the patients say they are taking (with possible 
omissions and errors), and what is actually collected from the 
pharmacy. Although collection from the pharmacy does not 
mean that the patient adheres correctly to treatment, clearly 
they cannot take a medication if it has not been collected 
from the pharmacy first. Another strength of this study is 
that we performed a sex-stratified analysis and compared our 
findings with a sample of the general population with same 
age and sex distribution.
A common limitation of studies that analyze pharmacy-
dispensed drug consumption is that they include data only on 
 
Cl
in
ica
l I
nt
er
ve
nt
io
ns
 in
 A
gi
ng
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
5.
21
0.
59
.2
16
 o
n 
18
-O
ct
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1156
gimeno-gracia et al
drugs covered by official medical prescriptions, that is, they 
do not include private health care treatments or alternative 
medicines. However, we do not believe that this is a signifi-
cant limitation in this study, as public health care coverage 
is universal in Spain. This study was conducted in a single 
hospital; therefore, the results have a limited generalizability. 
Likewise, the number of HIV-positive patients was small, 
with very few females, thus limiting the conclusions that can 
be drawn from the comparisons performed. This is a common 
limitation, due the low percentage of female HIV-positive 
patients in our setting.
It would be useful to expand this analysis to a larger 
population, involving several hospitals, to be able to validate 
these data. Likewise, a study on the appropriate use of CV 
drugs in the HIV-positive population would be worthwhile.
To reduce the risk of polypharmacy, the HIV and Aging 
Consensus Project recommends that clinicians managing older 
adults with HIV infection compile an accurate list of medica-
tions. In order to do so, they recommend patients use a single 
pharmacy, a pharmacy with an integrated computer network, 
or an HIV-specialized pharmacy. Involving a clinical phar-
macist can also help to reduce inappropriate prescribing and 
drug-related problems.7 Similar recommendations were made 
by the GESIDA (Study Group of AIDS) expert panel.8
Our study revealed a higher prevalence of polypharmacy 
in HIV-positive patients aged 50–64 years compared with 
members of the general population of the same age and sex. 
The greater use of non-ART drugs suggests a higher preva-
lence of comorbidity in this population. This highlights the 
need for close monitoring and regular medication review 
to ensure the timely detection of possible adverse events, 
selective adherence, drug–drug interactions, and potentially 
inappropriate medication, particular care should be taken 
with cardiovascular medications and anti-infectives.
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